Although the following needs a couple of updates (Striate+ has been approved in Canada and possibly Top-line results from Remplir™ US market authorisation study expected in Q4 CY24), I'm happy to see the latest presentation. It includes new information that should assist in aligning investor's expectations with the Company's:
https://www.bioshares.com.au/file/78/view/OCC.pdf
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.020(1.69%) |
Mkt cap ! $288.1M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.20 | $1.16 | $569.6K | 485.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 14715 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 16282 | 4 |
View Market Depth
| Last trade - 15.41pm 17/09/2025 (20 minute delay) ? |
| OCC (ASX) Chart |